Since glucose hypometabolism is one of the early and persistent signs of Alzheimer's disease, along with the fact that Alzheimer's brains possess impaired insulin signaling, icv STZ injections are used by some researchers to test pharmacological therapies for AD in preclinical settings [85, 86]. Here, INS is linked to early-onset autosomal dominant Alzheimer disease.